|Misonix CEO Honored as Life Science Business Person of the Year|
FARMINGDALE, N.Y.--(BUSINESS WIRE)--Jan. 15, 2007--Misonix, Inc. (NASDAQ: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced that Michael A. McManus, Jr., President and Chief Executive Officer of the Company, has been honored as Life Science Business Person of the Year by the Long Island Capital Alliance ("LICA") at The Annual Herman Fialkov Awards ceremony.
The Annual Herman Fialkov Awards is a business luncheon and award ceremony to celebrate Herman Fialkov, one of LICA's founding members. The Business Person of the Year Awards are presented to individuals who exude the qualities that Mr. Fialkov is known for - an eye for innovative thinking and the ability to execute business strategies, as well as those whose presence have made a profound impact on the business community. This year, awards have been given in three categories reflecting the major industries prevalent on Long Island: Life Science, Manufacturing and Technology.
Presenting the award to Mr. McManus on behalf of LICA was the event's moderator Matthew T. Crosson, Esq., President of the Long Island Association, the area's leading business association. Mr. Crosson noted that under Mr. McManus' leadership the Company has impressively executed a transition strategy from an industrial equipment company into a global leader in medical technology. As part of the winning nomination in the Life Science category, it was noted that Mr. McManus has taken his business acumen to drive medical innovation in 2006 that resulted in Misonix possessing the world's most advanced and extensive platform of therapeutic ultrasound medical devices for use in cancer treatment, wound debridement and other applications. In the past year, the Company has prepared for commercialization several new devices that increased the number of medical devices to 11 at the end of 2006, with three more expected in 2007 and significant other launches in the pipeline thereafter. With all products made at the Company's Farmingdale headquarters, Misonix is ensuring that Long Island makes a lasting impression on the global healthcare community.
About the Long Island Capital Alliance:
Since 1984, the Long Island Capital Alliance (www.licapital.org) has been stimulating business development on Long Island. The group provides entrepreneurs and investors an opportunity to network in a business-friendly environment, while delivering sound strategic advice at their monthly breakfast meetings. In addition, LICA seeks to promote business by bringing their signature event, the LI/NY Metro Capital Forum, to life every year. This highly successful investment conference and trade show is an avenue for regional businesses to seek funding from capital providers.
Misonix, Inc. (NASDAQ: MSON) designs, develops, manufactures, and markets medical, scientific, and industrial ultrasonic equipment, laboratory safety equipment, and air pollution control products. Misonix's ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, uncertainties as a result of research and development, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.